doi: 10.1001/jama.296.2.155.
Trials probe new agents for kidney cancer
- PMID: 16835411
- DOI: 10.1001/jama.296.2.155
Item in Clipboard
Trials probe new agents for kidney cancer
JAMA.
.
Erratum in
- JAMA. 2007 Apr 25;297(16):1774
No abstract available
Similar articles
-
Major treatment improvements encourage kidney cancer researchers to seek further gains.J Natl Cancer Inst. 2008 Sep 3;100(17):1202-3. doi: 10.1093/jnci/djn316. Epub 2008 Aug 26. J Natl Cancer Inst. 2008. PMID: 18728277 No abstract available.
-
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].Aktuelle Urol. 2009 Jan;40(1):27-30. doi: 10.1055/s-0028-1098786. Epub 2009 Jan 28. Aktuelle Urol. 2009. PMID: 19177318 German.
-
Newly approved therapies for RCC and their effect on the standard of care.Clin Adv Hematol Oncol. 2007 Jan;5(1):35-6, 66. Clin Adv Hematol Oncol. 2007. PMID: 17339824 No abstract available.
-
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844. Clin Cancer Res. 2007. PMID: 17606705 Review. No abstract available.
-
New therapeutic approaches in the management of metastatic renal cell carcinoma.J BUON. 2009 Jul-Sep;14(3):399-404. J BUON. 2009. PMID: 19810129 Review.
Cited by
-
Tissue-based research in kidney cancer: current challenges and future directions.Clin Cancer Res. 2008 Jun 15;14(12):3699-705. doi: 10.1158/1078-0432.CCR-07-4733. Clin Cancer Res. 2008. PMID: 18559586 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
